Growth Metrics

Castle Biosciences (CSTL) Revenue (2018 - 2025)

Castle Biosciences' Revenue history spans 8 years, with the latest figure at $87.0 million for Q4 2025.

  • On a quarterly basis, Revenue rose 0.81% to $87.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $344.2 million, a 3.66% increase, with the full-year FY2025 number at $344.2 million, up 3.66% from a year prior.
  • Revenue hit $87.0 million in Q4 2025 for Castle Biosciences, up from $83.0 million in the prior quarter.
  • Over the last five years, Revenue for CSTL hit a ceiling of $88.0 million in Q1 2025 and a floor of $22.8 million in Q2 2021.
  • Historically, Revenue has averaged $56.4 million across 5 years, with a median of $55.8 million in 2023.
  • Biggest five-year swings in Revenue: skyrocketed 78.99% in 2021 and later dropped 3.19% in 2025.
  • Tracing CSTL's Revenue over 5 years: stood at $25.0 million in 2021, then skyrocketed by 53.11% to $38.3 million in 2022, then soared by 72.47% to $66.1 million in 2023, then surged by 30.54% to $86.3 million in 2024, then grew by 0.81% to $87.0 million in 2025.
  • Business Quant data shows Revenue for CSTL at $87.0 million in Q4 2025, $83.0 million in Q3 2025, and $86.2 million in Q2 2025.